CRISPR Therapeutics AG
CRSP
$56.09
-$0.17-0.30%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -385.66M | -366.25M | -239.59M | -265.80M | -217.14M |
| Total Depreciation and Amortization | 19.16M | 19.26M | 19.32M | 19.50M | 19.62M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 59.39M | 47.95M | 54.81M | 54.97M | 58.10M |
| Change in Net Operating Assets | 628.00K | 156.27M | -23.35M | 69.57M | -20.00M |
| Cash from Operations | -306.47M | -142.77M | -188.82M | -121.76M | -159.42M |
| Capital Expenditure | -1.39M | -1.90M | -2.39M | -4.28M | -7.13M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -201.05M | -278.58M | -465.38M | -180.53M | 166.15M |
| Cash from Investing | -202.44M | -280.48M | -467.76M | -184.81M | 159.02M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 37.10M | 332.45M | 354.51M | 346.43M | 363.19M |
| Repurchase of Common Stock | -466.00K | -466.00K | -466.00K | -466.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 36.64M | 331.98M | 354.05M | 345.96M | 363.19M |
| Foreign Exchange rate Adjustments | 31.00K | -21.00K | 127.00K | 4.00K | 30.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -1.00K | -1.00K | -1.00K |
| Net Change in Cash | -472.24M | -91.29M | -302.41M | 39.40M | 362.82M |